OTCPK:MDXG

Stock Analysis Report

Executive Summary

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare.


Snowflake Analysis

Excellent balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has MiMedx Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDXG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.4%

MDXG

-1.3%

US Biotechs

-1.2%

US Market


1 Year Return

542.6%

MDXG

11.0%

US Biotechs

15.5%

US Market

Return vs Industry: MDXG exceeded the US Biotechs industry which returned 11% over the past year.

Return vs Market: MDXG exceeded the US Market which returned 15.5% over the past year.


Shareholder returns

MDXGIndustryMarket
7 Day1.4%-1.3%-1.2%
30 Day32.2%8.3%1.4%
90 Day49.0%13.6%4.7%
1 Year542.6%542.6%12.0%11.0%18.0%15.5%
3 Year-22.7%-22.7%27.4%23.4%44.8%35.4%
5 Year-32.8%-32.8%4.9%0.02%67.3%48.9%

Price Volatility Vs. Market

How volatile is MiMedx Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MiMedx Group undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether MiMedx Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MiMedx Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine MiMedx Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MiMedx Group regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is MiMedx Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

21.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MiMedx Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has MiMedx Group performed over the past 5 years?

19.4%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if MDXG has high quality earnings.

Growing Profit Margin: Insufficient data to determine if MDXG's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if MDXG's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare MDXG's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if MDXG's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: MDXG has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is MiMedx Group's financial position?


In this section we usually analyse MiMedx Group's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. MiMedx Group has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of MDXG’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when MiMedx Group's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is MiMedx Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDXG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDXG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDXG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of MiMedx Group's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Tim Wright (61yo)

0.6yrs

Tenure

0

Mr. Timothy R. Wright, also known as Tim, MBA, has been a Director of MiMedx Group, Inc. since June 17, 2019. Mr. Wright has been a Director of MiMedx Group, Inc. since June 17, 2019. He has been the Chief ...


Management Age and Tenure

1.2yrs

Average Tenure

61yo

Average Age

Experienced Management: MDXG's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Age and Tenure

3.9yrs

Average Tenure

73.5yo

Average Age

Experienced Board: MDXG's board of directors are considered experienced (3.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,669,87408 May 19
Richard Barry
EntityIndividual
Role
Member of the Board of Directors
Director
Shares468,600
Max PriceUS$3.86
BuyUS$1,894,11508 May 19
Richard Barry
EntityIndividual
Role
Member of the Board of Directors
Director
Shares668,600
Max PriceUS$3.90
SellUS$1,474,47008 May 19
Prescience Investment Group LLC
EntityCompany
Shares603,925
Max PriceUS$2.53
BuyUS$624,41008 May 19
Prescience Investment Group LLC
EntityCompany
Shares250,000
Max PriceUS$2.51
BuyUS$2,977,94302 Apr 19
Prescience Investment Group LLC
EntityCompany
Shares1,077,975
Max PriceUS$3.15
SellUS$5,589,78724 Jan 19
Okumus Fund Management, Ltd.
EntityCompany
Shares1,991,700
Max PriceUS$2.88

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Management Team

  • David Mason (72yo)

    Chief Medical Officer

    • Tenure: 1yrs
  • Ed Borkowski (61yo)

    Executive Officer

    • Tenure: 0.08yrs
    • Compensation: US$891.14k
  • Tim Wright (61yo)

    CEO & Director

    • Tenure: 0.6yrs
  • Robert Borchert

    Vice President of Investor Relations

    • Tenure: 0yrs
  • John Harris (50yo)

    Senior Vice President of Marketing & Business Development

    • Tenure: 1yrs
  • Thomas Koob (70yo)

    Chief Scientific Officer

    • Tenure: 12.8yrs
    • Compensation: US$183.75k
  • Rebeccah J. Brown (46yo)

    Vice President of Global Regulatory Affairs

    • Tenure: 6.7yrs
    • Compensation: US$198.47k
  • Butch Hulse (45yo)

    General Counsel & Secretary

    • Tenure: 0yrs
  • Mark Graves

    Chief Compliance Officer

    • Tenure: 1.4yrs
  • Scott Turner

    Senior Vice President of Operations & Procurement

    • Tenure: 2.7yrs
    • Compensation: US$577.86k

Board Members

  • James Andrews (76yo)

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • J. Dewberry (75yo)

    Independent Director

    • Tenure: 10.3yrs
    • Compensation: US$69.00k
  • Rick Barry (60yo)

    Director

    • Tenure: 0.5yrs
  • Chuck Koob (75yo)

    Director

    • Tenure: 11.8yrs
    • Compensation: US$42.00k
  • Tim Wright (61yo)

    CEO & Director

    • Tenure: 0.6yrs
  • Charlie Evans (72yo)

    Lead Director

    • Tenure: 0yrs
    • Compensation: US$97.17k
  • Robert Guldberg

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Glenn Gaston

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Neil Yeston (76yo)

    Independent Director

    • Tenure: 7.3yrs
    • Compensation: US$66.17k
  • M. Behrens Wilsey (66yo)

    Chairman of the Board

    • Tenure: 0.5yrs

Company Information

MiMedx Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MiMedx Group, Inc.
  • Ticker: MDXG
  • Exchange: OTCPK
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$783.560m
  • Shares outstanding: 108.83m
  • Website: https://www.mimedx.com

Number of Employees


Location

  • MiMedx Group, Inc.
  • 1775 West Oak Commons Court, NE
  • Marietta
  • Georgia
  • 30062
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDXGOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2008

Biography

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. I ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/06 00:10
End of Day Share Price2019/12/05 00:00
Earnings2017/09/30
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.